Tscan Therapeutics IncTCRX
Price$0.31

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $7.1M+152.5% YoYTTM through 30 Jun 2026
Net Income -$117.7MTTM through 30 Jun 2026
Free Cash Flow -$118.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin29.4%
Operating Margin-2,967.3%
Net Margin-1,655.4%

Returns

-113.0%ROE
-59.8%ROA

Balance Sheet Health

Debt / Equity0.95x
Current Ratio6.65x
Net Debt-$35.5Mnet cash position
Cash & Equivalents$100.2M

Quality Metrics

Altman Z-Score-6.23
Piotroski F-Score4 / 9
FCF Margin-1,665.6%
Rule of 40-1,659.3
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $10.3M
Diluted EPS-$0.90TTM
'21'22'23'24'25
FY2025: $-1.00

Dividend

No dividend

Capital Allocation

Capex Intensity30.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.